Related Experiment Video

Updated: Aug 15, 2026

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay
11:14

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

Published on: November 11, 2013

The mutagenic and carcinogenic properties of three second generation antitumour platinum compounds: a comparison with

R Chibber1, M J Ord

  • 1Department of Biology, Southampton University, Hants, U.K.

European Journal of Cancer & Clinical Oncology
|January 1, 1989
PubMed

Insights

Second-generation platinum compounds were tested for DNA damage and mutation induction in mammalian cells. Cisplatin and spiroplatin showed higher mutagenicity and carcinogenicity than carboplatin and iproplatin.

Area of Science:

  • Toxicology
  • Genetics
  • Cancer Research

Background:

  • Platinum-based chemotherapy agents are widely used in cancer treatment.
  • Second-generation platinum compounds were developed to improve efficacy and reduce toxicity.
  • Understanding the genotoxic and carcinogenic potential of these agents is crucial for patient safety.

Purpose of the Study:

  • To evaluate the cytotoxicity, mutagenicity, and transforming potentials of three second-generation platinum compounds.
  • To compare the genotoxic effects of cisplatin, spiroplatin, carboplatin, and iproplatin in mammalian cells.

Main Methods:

  • Mammalian cell assays were used, including mutation induction at the HGPRT locus and sister chromatid exchange (SCE) analysis.
  • BHK transformation assay was employed to assess potential carcinogenicity.
  • Experiments were conducted at equitoxic doses to ensure fair comparison.

Main Results:

  • All tested platinum compounds induced mutations and DNA damage (SCE) in Chinese hamster V 79 cells.
  • Mutagenicity order at equitoxic doses: cisplatin > spiroplatin > carboplatin > iproplatin.
  • Carcinogenicity potential order: cisplatin (high) > spiroplatin (moderate) > carboplatin and iproplatin (weak).

Conclusions:

  • Second-generation platinum compounds exhibit varying levels of mutagenicity and carcinogenicity.
  • Cisplatin and spiroplatin demonstrate greater genotoxic and carcinogenic potential compared to carboplatin and iproplatin.
  • These findings highlight the importance of assessing the safety profile of platinum-based drugs.

More Related Videos

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Related Concept Videos

Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Spontaneous and Induced Mutations01:30

Spontaneous and Induced Mutations

Spontaneous mutations arise infrequently during DNA replication due to errors in the process. A key factor behind these errors is tautomeric shifts in nitrogenous bases, where bases transition from keto to enol forms or amino to imino forms. This shift can alter base-pairing rules, leading to mutations. Additionally, reactive oxygen species (ROS) arising from aerobic metabolism can damage DNA, resulting in depurination (loss of a purine base) or depyrimidination (loss of a pyrimidine base).